医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Pharmatech and InQui Capital Team Up to Offer Development Services to Life Science Startups

2015年06月02日 PM10:06
このエントリーをはてなブックマークに追加


 

HAYWARD, Calif.

Pharmatech Associates and InQui Capital of Hong Kong today announced the Pharmatech Connect program, a collaboration bringing development opportunities to early stage life science technology companies in the areas of investments, market expansion and strategic alliances worldwide.

Pharmatech Connect is a program created by Pharmatech Associates to provide early to mid-stage life sciences companies with financial resources to enable and accelerate development. The program services include identification and introduction of investors to cover the full range of development costs encompassing expertise in: global regulatory, technical development, manufacturing and compliance requirements, strategic partnering, business development and global healthcare investment services.

“Leveraging our experience along with that of InQui Capital, Pharmatech Connect is intended to bring together resources to boost the development of novel; biologicals, pharmaceuticals and medical devices,” said Warren Baker, Chief Executive Officer, Pharmatech Associates. “The healthcare market is global, and we are working locally and globally with companies to develop better drugs and therapies that result in healthier populations.”

“InQui Capital is pleased to team up with Pharmatech Associates to help life sciences companies realize their business goals and expand into the China market, one of the largest in the world,” said Dr. Juliana Xu, InQui Capital.

About Pharmatech Associates

Pharmatech Associates provides consulting and services to the regulated life science industry. Pharmatech’s services cover four spheres of technical expertise that are necessary throughout the complete product development lifecycle: Product and Process Development, Compliance, Regulatory, and Validation. This interconnected framework of services denotes the Pharmatech EcosystemTM. Pharmatech advises clients that range in size from startups to large multi-national corporations on projects in Asia, Europe and North America from its headquarters in the San Francisco Bay Area.

About InQui Capital

InQui Capital Ltd. is a Hong Kong-based consulting and investment firm focusing on life science-related sectors. InQui serves as a gateway between China and the West by helping small to mid-size companies find strategic partners both locally and globally. Its founders have extensive experience and knowledge in the global health care market, ranging from fund raising, IPO, cross-border mergers & acquisitions, intellectual property and securities law. InQui assists clients from the inception of their business, grows with them through fund raising, technology transfers, corporate development, and builds them into leaders in their fields.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150602005130/en/

CONTACT

SIPR for Pharmatech
Judy Curtis, + 1 650-274-1509
judy@sipr.com
or
Pharmatech
Jerry
Beers, + 1 510-732-0177
jbeers@pharmatechassociates.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions
  • Taiwan Innotech Expo (TIE) Showcases Strong Ecosystems in the Post-Pandemic World
  • Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market
  • 随着越来越多的客户和合作伙伴使用Denodo冠状病毒数据门户计划来对抗和最小化COVID-19的影响,其采纳率在不断提高
  • GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise